Reported 1 day ago
BMO Capital has maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME), setting a price target of $10. The analyst highlights the company's innovative gene editing technology and a recent $39 million funding boost from the Cystic Fibrosis Foundation that underscores its potential in treating cystic fibrosis. With a notable 90% editing efficiency demonstrated in a patient, the company's credibility and growth outlook are strengthened.
Source: YAHOO